HOOKIPA Pharma to Participate in Upcoming Investor Conferences in May

Rhea-AI Summary

HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced its participation in several upcoming virtual investor conferences. Key events include the 7th Annual Truist Securities Life Sciences Summit on May 4, the Bank of America Health Care Conference on May 13, the Morgan Stanley Asia Healthcare Conference on May 13-14, and the RBC Capital Markets Global Healthcare Conference on May 18. Live webcasts will be accessible on HOOKIPA's website, with replays available for 30 days. HOOKIPA is focused on developing innovative immunotherapeutics using its proprietary arenavirus platform.

NEW YORK and VIENNA, Austria, April 29, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA’s management team will participate and present at the following upcoming virtual investor conferences:

• 7th Annual Truist Securities Life Sciences Summit, May 4 – 5, 2021
  Fireside Chat: May 4, 1:50pm ET

• Bank of America 2021 Health Care Conference, May 10 – 13, 2021
  Presentation: May 13, 1:15pm ET

• Morgan Stanley Virtual Asia Healthcare Conference, May 13 - 14, 2021
  
  
• RBC Capital Markets Global Healthcare Conference, May 18 - 20, 2021
  Fireside Chat: May 18, 9:45am ET

The live audio webcasts of the fireside chats and presentation will be available within the Investors & Media section of HOOKIPA’s website at https://ir.hookipapharma.com/events. An archived replay will be accessible for 30 days following the event.

About HOOKIPA
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that reprograms the body’s immune system.

HOOKIPA’s proprietary arenavirus-based technologies, non-replicating and replicating, induce robust antigen-specific CD8+ T cells and pathogen-neutralizing antibodies. HOOKIPA’s viral vectors target antigen presenting cells in vivo to activate the immune system. Both technologies enable repeat administration to augment and refresh immune responses. As a monotherapy not used in combination, our replicating arenavirus technology has the potential to induce CD8+ T cell response levels previously not achieved by other immuno-therapy approaches.

HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens. The lead replicating arenavirus oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papilloma Virus 16-positive cancers in a Phase 1/2 clinical trial.

HOOKIPA’s non-replicating prophylactic Cytomegalovirus (CMV) vaccine candidate, HB-101, is currently in a Phase 2 clinical trial for patients awaiting kidney transplantation. To expand its infectious disease portfolio, HOOKIPA entered into a collaboration and licensing agreement with Gilead Sciences, Inc. to research arenavirus-based functional cures for HIV and chronic Hepatitis B infections.

Find out more about HOOKIPA online at www.hookipapharma.com.

For further information, please contact:

Media	Investors
Nina Waibel	Matt Beck
Senior Director - Communications	Executive Director - Investor Relations
nina.waibel@hookipapharma.com	matthew.beck@hookipapharma.com

FAQ

What conferences will HOOKIPA participate in during May 2021?

HOOKIPA will participate in the Truist Securities Life Sciences Summit on May 4, the Bank of America Health Care Conference on May 13, the Morgan Stanley Asia Healthcare Conference on May 13-14, and the RBC Capital Markets Global Healthcare Conference on May 18.

When is HOOKIPA's fireside chat at the Truist Securities Life Sciences Summit?

HOOKIPA's fireside chat at the Truist Securities Life Sciences Summit is scheduled for May 4, 2021, at 1:50 PM ET.

How can I access HOOKIPA's conference presentations?

You can access HOOKIPA's live audio webcasts and archived presentations on the Investors & Media section of their website.

What is the focus of HOOKIPA's immunotherapeutics?

HOOKIPA focuses on developing immunotherapeutics using its proprietary arenavirus platform to target various cancers and infectious diseases.

What is the status of HOOKIPA's clinical trials?

HOOKIPA is currently conducting Phase 1/2 clinical trials for its lead oncology product candidates and a Phase 2 trial for its non-replicating CMV vaccine candidate.